ZEGA Investments LLC Makes New $1.16 Million Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

ZEGA Investments LLC bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,229 shares of the medical equipment provider’s stock, valued at approximately $1,163,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Atala Financial Inc bought a new position in Intuitive Surgical during the fourth quarter worth about $25,000. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter valued at about $26,000. BankPlus Trust Department bought a new stake in shares of Intuitive Surgical during the fourth quarter valued at approximately $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at $31,000. Finally, Decker Retirement Planning Inc. bought a new stake in Intuitive Surgical during the 4th quarter worth about $36,000. Institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the completion of the transaction, the chief financial officer now owns 2,630 shares in the company, valued at approximately $1,502,019.30. This represents a 3.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the completion of the sale, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock worth $17,691,621 in the last quarter. Company insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their price target on Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Jefferies Financial Group upped their target price on Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. Bernstein Bank boosted their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Evercore ISI boosted their target price on Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Finally, Piper Sandler restated an “overweight” rating and set a $670.00 price objective (up from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $611.86.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $492.49 on Friday. Intuitive Surgical, Inc. has a 12 month low of $364.17 and a 12 month high of $616.00. The company has a market capitalization of $175.41 billion, a price-to-earnings ratio of 76.83, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. The firm’s fifty day moving average price is $562.24 and its 200 day moving average price is $531.34.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.